StocksFundsScreenerSectorsWatchlists
ENOB

ENOB - Enochian Biosciences, Inc. Stock Price, Fair Value and News

Market Closed

ENOB Stock Price

View Fullscreen

ENOB RSI Chart

ENOB Valuation

Market Cap

38.1M

Price/Earnings (Trailing)

-0.92

Price/Sales (Trailing)

889.77

EV/EBITDA

-0.91

Price/Free Cashflow

-3.19

ENOB Price/Sales (Trailing)

ENOB Profitability

EBT Margin

-96236.35%

Return on Equity

-94.58%

Return on Assets

-71.07%

Free Cashflow Yield

-31.34%

ENOB Fundamentals

ENOB Revenue

Revenue (TTM)

42.8K

ENOB Earnings

Earnings (TTM)

-41.2M

Earnings Growth (Yr)

-1.6%

Earnings Growth (Qtr)

50.64%

Breaking Down ENOB Revenue

Last 7 days

20.3%

Last 30 days

14.7%

Last 90 days

-43.0%

Trailing 12 Months

-71.7%

How does ENOB drawdown profile look like?

ENOB Financial Health

Current Ratio

0.17

ENOB Investor Care

Shares Dilution (1Y)

159.78%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
201643.7K43.1K00
201500043.7K
201355.3K47.8K40.3K32.8K
201200062.8K

Tracking the Latest Insider Buys and Sells of Enochian Biosciences, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 26, 2023
sindlev rene
acquired
1,000,000
0.53
1,886,790
-
Mar 17, 2023
sindlev rene
acquired
1,000,000
1.14
877,193
-
Oct 13, 2022
weird science llc
acquired
-
-
1,216,470
-
Oct 13, 2022
william anderson wittekind
acquired
-
-
1,216,470
-
Jun 08, 2022
sindlev rene
sold
-
-
-125,000
-
Jun 08, 2022
sindlev rene
sold
-
-
-128,493
-
May 18, 2022
sindlev rene
bought
1,027,940
8.00
128,493
-
May 18, 2022
gumrukcu serhat
sold
-2,027,940
8.00
-253,493
-
May 18, 2022
sindlev rene
bought
1,000,000
8.00
125,000
-
Apr 15, 2022
weird science llc
sold
-
-
-4,961,360
-

1–10 of 50

Which funds bought or sold ENOB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
added
43.78
23,817
1,236,640
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
new
-
81,602
81,602
-%
Feb 26, 2024
Virtu Financial LLC
new
-
59,000
59,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
179,841
179,841
-%
Feb 14, 2024
BNP PARIBAS FINANCIAL MARKETS
reduced
-64.74
-11,382
3,794
-%
Feb 14, 2024
MSA Advisors, LLC
new
-
79,250
79,250
0.03%
Feb 14, 2024
LAZARD ASSET MANAGEMENT LLC
new
-
12,000
12,000
-%
Feb 14, 2024
Balyasny Asset Management L.P.
new
-
81,637
81,637
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
reduced
-34.12
-456,627
400,415
-%
Feb 14, 2024
Laurion Capital Management LP
new
-
194,904
194,904
-%

1–10 of 38

Are Funds Buying or Selling ENOB?

Are funds buying ENOB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ENOB
No. of Funds

Unveiling Enochian Biosciences, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 22, 2024
abildgaard ole
7.6%
11,157,447
SC 13G/A
Feb 16, 2024
sindlev rene
10.28%
14,945,971
SC 13D/A
Feb 16, 2024
william anderson wittekind
13.2%
18,956,376
SC 13D/A
Jan 24, 2024
sindlev rene
20.9%
14,945,971
SC 13D/A
Jan 24, 2024
sindlev rene
23.3%
13,861,471
SC 13D/A
Jan 24, 2024
sindlev rene
19.6%
11,031,280
SC 13D/A
Jan 24, 2024
sindlev rene
18.6%
9,702,808
SC 13D/A
Jan 24, 2024
sindlev rene
20.9%
9,685,251
SC 13D/A
Jan 24, 2024
sindlev rene
24.2%
9,515,137
SC 13D/A
Jan 24, 2024
sindlev rene
23.2%
9,420,869
SC 13D/A

Recent SEC filings of Enochian Biosciences, Inc.

View All Filings
Date Filed Form Type Document
Mar 19, 2024
4
Insider Trading
Mar 13, 2024
3
Insider Trading
Mar 13, 2024
4
Insider Trading
Mar 13, 2024
8-K
Current Report
Mar 07, 2024
8-K
Current Report
Mar 05, 2024
8-K
Current Report
Feb 28, 2024
4
Insider Trading
Feb 23, 2024
3
Insider Trading
Feb 23, 2024
D
D
Feb 22, 2024
4
Insider Trading

Enochian Biosciences, Inc. News

Latest updates
InvestorPlace • 8 months ago
Business Wire • 22 months ago

Enochian Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2016Q22016Q12015Q42013Q42013Q32013Q22013Q12012Q4
Revenue-244-42,525285925-31,558-
Gross Profit-213-37,281-40,528-15,273-36,92816,198-
Income Taxes1276.7%397,824-33,808-340,103-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets0.8%58.0058.0058.0079.0080.0083.0085.00180183184190174173175178181178181180178181
  Current Assets26.1%2.002.003.004.005.008.0010.0012.0015.0015.0021.005.004.006.009.0011.009.0011.0012.0011.0013.00
    Cash Equivalents-53.4%0.001.002.003.004.008.009.0011.0014.0015.0021.005.003.006.009.0011.009.0011.0012.0010.0013.00
  Net PPE3.0%0.000.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00
  Goodwill0%12.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.00
Liabilities33.3%14.0011.0012.0013.0013.0013.0012.0019.0018.00-15.0011.0011.0011.0012.0010.007.008.007.0025.0025.00
  Current Liabilities36.3%14.0010.0011.0012.0011.007.006.008.006.001.002.001.002.001.001.001.001.001.001.002.002.00
Shareholder's Equity-6.7%44.0047.0047.0066.0067.0070.0073.00161166167175162162164166170171172173153155
  Retained Earnings-1.8%-257-253-244-220-216-212-204-114-107-101-90.91-73.55-69.52-66.58-64.19-60.09-58.58-56.86-52.77-53.94-51.21
  Additional Paid-In Capital0.4%301300291287283282277275274268266236231231230230230229226206206
Shares Outstanding2.3%67.0066.0064.0058.0055.0055.0053.0053.0053.0052.0052.0048.0047.0047.00-------
Float-----45.00---243---83.00---69.00---72.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-13.3%-3,146-2,777-2,261-3,307-3,551-2,653-3,050-2,784-4,620-5,276-13,028-2,330-2,496-2,755-2,245-3,838-2,575-1,800-2,218-2,737-1,754
  Share Based Compensation1.6%999984--8201,026-1105782,0432,728186352359326-11.25-28.0969023416297.001,780
Cashflow From Investing94.6%-57.33-1,057-6.14-------5.16-38.17--10.72--10.45-41.69-63.70-68.6217.00-92.63-332
Cashflow From Financing11.1%2,8472,5631,2482,109-3001,4581,0702302,951-29,2033,439-40.41--6,200-1,0004,320--

ENOB Income Statement

2023-12-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Operating Expenses    
General and administrative$ 3,616,392$ 4,013,063$ 11,906,602$ 8,569,903
Research and development620,521325,9591,187,1652,931,334
Depreciation and amortization33,16228,84460,42257,245
Total Operating Expenses4,270,0754,367,86613,154,18911,558,482
LOSS FROM OPERATIONS(4,270,075)(4,367,866)(13,154,189)(11,558,482)
Other Income (Expenses)    
Loss on extinguishment of debt(120,018)
Loss on extinguishment of contingent consideration(419,182)
Interest expense(274,984)(92,892)(454,255)(188,477)
Interest and other income15,9383,01024,3138,633
Total Other Income (Expense)(259,046)(89,882)(549,960)(599,026)
NET LOSS$ (4,529,121)$ (4,457,748)$ (13,704,149)$ (12,157,508)

ENOB Balance Sheet

2023-12-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2023
Jun. 30, 2023
CURRENT ASSETS:  
Cash$ 243,980$ 1,874,480
Notes receivable1,073,625
Prepaids and other assets1,085,545690,925
Total Current Assets2,403,1502,565,405
Property and equipment, net496,896508,989
OTHER ASSETS:  
Definite life intangible assets, net32,64139,676
Indefinite life intangible assets42,611,00042,611,000
Goodwill11,640,00011,640,000
Deposits and other assets21,74221,741
Operating lease right-of-use assets812,691913,985
Total Other Assets55,118,07455,226,402
TOTAL ASSETS58,018,12058,300,796
CURRENT LIABILITIES:  
Accounts payable – trade5,577,9175,296,823
Accrued expenses783,601723,173
Other current liabilities669,384184,733
Current portion of operating lease liabilities218,085193,422
Notes payable, net3,940,0004,624,947
Convertible notes payable2,569,379
Total Current Liabilities13,758,36611,023,098
NON-CURRENT LIABILITIES:  
Operating lease liabilities, net of current portion664,218775,587
 Total Non-Current Liabilities664,218775,587
Total Liabilities14,422,58411,798,685
 Commitments and Contingencies
STOCKHOLDERS’ EQUITY:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; Series A Convertible Preferred;1,000,000 shares designated; 561,010 shares issued and outstanding at December 31, 2023 and zero 0 shares issued and outstanding at June 30, 202356
Common Stock, par value $0.0001, 100,000,000 shares authorized, 67,224,089 shares issued and outstanding at December 31, 2023, and 63,698,144 shares issued and outstanding at June 30, 20236,7246,371
Additional paid-in capital301,349,389290,554,875
Accumulated deficit(257,733,402)(244,029,253)
Accumulated other comprehensive loss(27,231)(29,882)
Total Stockholders’ Equity43,595,53646,502,111
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 58,018,120$ 58,300,796

About Enochian Biosciences, Inc.

ENOB

Enochian Biosciences, Inc. Frequently Asked Questions


What is the ticker symbol for Enochian Biosciences, Inc.? What does ENOB stand for in stocks?

ENOB is the stock ticker symbol of Enochian Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enochian Biosciences, Inc. (ENOB)?

As of Wed Jan 31 2024, market cap of Enochian Biosciences, Inc. is 38.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENOB stock?

You can check ENOB's fair value in chart for subscribers.

What is the fair value of ENOB stock?

You can check ENOB's fair value in chart for subscribers. The fair value of Enochian Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Enochian Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENOB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Enochian Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether ENOB is over valued or under valued. Whether Enochian Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Enochian Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENOB.

What is Enochian Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jan 31 2024, ENOB's PE ratio (Price to Earnings) is -0.92 and Price to Sales (PS) ratio is 889.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENOB PE ratio will change depending on the future growth rate expectations of investors.